NCT04699630
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04699630
Title A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Birmingham Alabama 35249 United States Details
Highlands Oncology Group Springdale Arkansas 72762 United States Details
City of Hope Duarte California 91010 United States Details
Florida Cancer Specialists-South Fort Myers Florida 33901 United States Details
Florida Cancer Specialists-North St. Petersburg Florida 33705 United States Details
Washington University School of Medicine St Louis Missouri 63110 United States Details
Rutgers-Cancer Institute of New Jersey New Brunswick New Jersey 08903 United States Details
Levine Cancer Institute Charlotte North Carolina 28204 United States Details
SCRI Oncology Partners Nashville Tennessee 37203 United States Details
Tennessee Oncology Nashville Tennessee 37203 United States Details
Seattle Cancer Care Alliance Seattle Washington 98109 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field